Monetary Management Group Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Monetary Management Group Inc. sold 680 shares of Regeneron Pharmaceuticals, reducing its holdings by 38.1% to a total of 1,107 shares, which were valued at $702,000.
• Regeneron's recent quarterly earnings surpassed analysts' expectations, reporting $12.89 EPS against a consensus estimate of $8.43, with revenue hitting $3.68 billion.
• The company declared a quarterly dividend of $0.88, translating to an annual yield of 0.6%, to be paid to shareholders on September 3rd.

Monetary Management Group Inc. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 38.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,107 shares of the biopharmaceutical company's stock after selling 680 shares during the quarter. Monetary Management Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $702,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Tompkins Financial Corp purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Finally, Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on REGN shares. The Goldman Sachs Group decreased their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Citigroup restated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Morgan Stanley restated an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Guggenheim increased their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Trading Down 1.5%

Shares of NASDAQ:REGN traded down $8.68 on Friday, hitting $589.48. 1,438,624 shares of the company's stock were exchanged, compared to its average volume of 1,026,661. The stock has a market capitalization of $62.48 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The business's 50 day simple moving average is $550.48 and its two-hundred day simple moving average is $590.42.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $11.56 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.